DeutschNewstral
Article
Mmarketwatch.com on 2017-06-02 14:20
Bluebird Bio stock jumps 7% after Maxim Group upgrades to buy
Related news
- BBluebird Bio Gains on Analyst's Buy Callbarrons.com
- MBluebird Bio shares decline 6% after Morgan Stanley downgrademarketwatch.com
Bluebird Bio Inc: Positive Trials Will Send BLUE Stock Soaringprofitconfidential.com- BBluebird Bio Gains on Promising Cancer-Drug Databarrons.com
- MJ.P. Morgan analyst crowns Bluebird Bio the ‘clear winner’ at major cancer conferencemarketwatch.com
- MBluebird Bio shares lift 9% on CAR-T cancer therapy resultsmarketwatch.com
- MUPDATE: Bluebird Bio stock rises 7.4% on positive data from ongoing early-stage clinical trialmarketwatch.com
- MFacebook stocks jumps 2.5% after Instinet upgrades to buymarketwatch.com
- ILendingClub shares spike 9% after Maxim upgrade: is it time to buy?invezz.com
- BBluebird bio Is ‘Remarkably Undervalued,’ Analyst Saysbarrons.com
- MMercadoLibre stock jumps after KeyBanc upgrades to buy on strength of LatAm payments opportunitiesmarketwatch.com
- MJetBlue stock jumps 2.4% premarket after Buckingham upgrades it to buymarketwatch.com
- MPandora stock jumps after Raymond James upgrades to strong buy, praises AdsWizz acquisitionmarketwatch.com
- BRealReal Jumps 5% After BofA Upgrades Stock to Buy 2 min readbarrons.com
Cambridge's bluebird bio expanding Kendall Square HQbizjournals.com
Bluebird Bio Sickle-Cell Therapy Helped Teenwsj.com- MUPDATE: Caterpillar stock jumps as Goldman upgrades to Conviction Buy listmarketwatch.com
- MCanopy Growth Stock Jumps After Merrill Lynch Upgrades It to Buymarketwatch.com
- Exec at Cambridge's bluebird bio heads to startup Be Biobizjournals.com
- Bluebird bio completes spinout of oncology business 2seventy biobizjournals.com